Jose Miguel T. D.
- Country
- France
- Department
- 2410: Hématologie oncologie
Research Overview
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
- Evaluation of Ropeginterferon Alfa-2b Efficacy and Safety in Essential Thrombocythaemia Patients Intolerant, Refractory, or Ineligible for Cytoreductive Treatments
Data & Insights
Has run more than one trial at 185 of 337 partner sites.
Specializations
Myeloid Disorders
Specialized in treating various forms of myelodysplastic syndromes (MDS), including both higher-risk and lower-risk variants. Investigates novel therapeutic approaches for patients who are ineligible for allogenic transplantation and those requiring transfusion support.
- Higher-risk MDS treatments
- Lower-risk MDS management
- Transfusion dependency solutions
Leukemia Research
Focuses on advancing treatment options for chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). Explores innovative therapeutic combinations and treatment discontinuation strategies in CML patients.
- Tyrosine kinase inhibitor therapy
- Novel drug combinations
- Treatment optimization strategies
Myeloproliferative Neoplasms
Conducts research in various myeloproliferative disorders, including myelofibrosis, polycythemia vera, and essential thrombocythemia. Specializes in investigating treatments for disease-related complications and symptoms.
- Primary and secondary myelofibrosis
- Anemia management
- Spleen volume reduction therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.